<DOC>
	<DOCNO>NCT00859183</DOCNO>
	<brief_summary>Despite recent advance interventional cardiology include success drug-eluting stent de-novo coronary lesion , treatment in-stent restenosis remain challenge clinical issue . Given efficacy systemic sirolimus administration prevent neointimal hyperplasia animal model halt even reverse progression allograft vasculopathy , aim present double-blind , placebo-controlled study evaluate efficacy 10-day oral sirolimus treatment two different load regimen prevention recurrent restenosis patient in-stent restenosis .</brief_summary>
	<brief_title>Oral Sirolimus In-Stent Restenosis</brief_title>
	<detailed_description>Three-hundred symptomatic patient in-stent restenotic lesion randomly assign one three treatment arm : placebo , usual dose high dose sirolimus . Patients receive cumulative loading dose 0 , 8 24 mg sirolimus two day prior day repeat intervention follow maintenance therapy 2 mg/day 7 day . Angiographic restenosis 6-months angiography primary end point study .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients angina pectoris exerciseinduced ischemia presence angiographically significant instentrestenosis native coronary artery . Patients acute coronary syndrome severe infectious disease presence severe kidney failure ( serum creatinine &gt; 2.2 mg/dl ) contraindication sirolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>in-stent restenosis</keyword>
	<keyword>stent</keyword>
	<keyword>sirolimus</keyword>
</DOC>